What Do Analysts Think About Amgen Inc. (AMGN)?

Amgen Inc. (NASDAQ:AMGN) is one of the best drug stocks to buy right now. Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with total revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues.

Dogs of the Dow: Why Amgen’s (AMGN) Dividend Power Makes it a Standout Pick

In a report released on September 5, Vamil Divan from Guggenheim maintained a Hold rating on Amgen Inc., setting a price target of $288.00.

However, Raymond James assumed coverage of the stock on September 3 with a Market Perform rating without assigning a price target.

The firm told investors that a meaningful extent of Amgen Inc.’s valuation is for MariTide, whose clinical profile warrants its place as more of a niche player in the obesity market.

Amgen Inc.’s analyst consensus is a Moderate Buy, with its median price target of $276.39 implying an upside of 12.16% from current levels.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.